Corri Xr Therapeutics Announces Deborah Moorad As Its New Chief Executive Officer

Sep 19, 2023•almost 2 years ago

Company

CorriXR Therapeutics

NewarkBiotechnology

Description

CorriXR Therapeutics, Inc., an oncology-focused biotherapeutics company developing breakthrough technology that overcomes drug resistance in solid tumors, announced that Deborah Moorad, MBA, has been named the company’s new chief executive officer. Moorad, who previously served as CEO of Nature Technology Corp., and is an Entrepreneur-in-Residence at Cortado Ventures, succeeds co-founder Eric B. Kmiec, Ph.D., who has been appointed chief scientific officer.

Company Information

Company

CorriXR Therapeutics

Location

550 S College Ave, Suite 107

Newark, Delaware, United States

About

CorriXR Therapeutics is on the clinical frontier of gene editing as a transformative pre-clinical stage biotechnology company with a ground-breaking in vivo gene editing therapeutic platform technology. CorriXR Therapeutics advances CRISPR/Cas gene editing technology to develop new genetic medicines directed against drug-resistant solid tumors.

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months

Related People

Jan hidden

hidden

Eric hidden